Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank

Adriano R Tonelli¹
Farshid Rouhani¹
Ning Li²
Pam Schreck¹
Mark L Brantly¹

¹Alpha-1 Research Program, Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, ²Department of Epidemiology and Biostatistics, University of Florida, Gainesville, Florida, USA

Introduction: Intravenous augmentation therapy with purified intravenous alpha-1 antitrypsin replaces the deficient protein and is the only currently approved treatment for alpha-1 antitrypsin deficiency (AATD) related lung disease. While augmentation therapy has been available for more than 20 years, there are a limited number of studies evaluating the effect of augmentation on lung function.

Material and methods: We examined the decline in forced expiratory volume in one second (FEV₁) in patients enrolled in the Alpha-1 Foundation DNA and Tissue Bank in relation to the use or not of alpha-1 antitrypsin augmentation therapy. For the purpose of our analysis we included 164 patients with AATD and PI ZZ genotype.

Results: Mean age of the patients was 60 years, 52% were females, 94% were white and 78% ex-smokers. The mean FEV₁ at baseline was 1.7 L and the mean FEV₁ % of predicted was 51.3%. The mean follow-up time was 41.7 months. A total of 124 (76%) patients received augmentation therapy (augmented group) while 40 patients (24%) did not received it (non-augmented group). When adjusted by age at baseline, sex, smoking status, baseline FEV₁ % of predicted, the mean overall change in FEV₁ was 47.6 mL/year, favoring the augmented group (Δ FEV₁ 10.6 $\pm$ 21.4 mL/year) in comparison with the non-augmented group (Δ FEV₁ -36.96 $\pm$ 12.1 mL/year) ($P = 0.05$). Beneficial Δ FEV₁ were observed in ex-smokers and the group with initial FEV₁ % of predicted of <50%. No differences were observed in mortality.

Conclusions: In conclusion, augmentation therapy improves lung function in subjects with AATD when adjusted by age, gender, smoking status and baseline FEV₁ % of predicted. The beneficial effects were noted in ex-smoker subjects with FEV₁ below 50% of predicted.

Keywords: alpha-1 antitrypsin deficiency, augmentation therapy, forced expiratory volume in one second

Introduction

Alpha-1 antitrypsin deficiency (AATD) is an autosomal codominant inherited condition characterized by low levels of alpha-1 antitrypsin in serum and tissues. This protein, primarily produced in the liver, is the most prevalent protease inhibitor in serum and its main function is to inhibit neutrophil elastase, a proteolytic enzyme capable of destroying alveolar structures.¹⁻³ The imbalance between proteases and antiproteases leads to alveolar destruction that in turn results in a rapid decline of the forced expiratory volume in one second (FEV₁) and the development of emphysema at an early age.⁴ Factors associated with a more rapid FEV₁ decline include male gender, older age (specially after 50 years), low BMI, current smoking status, presence of bronchodilator response, frequent respiratory exacerbations and mid-range FEV₁ % of

Correspondence: Mark L Brantly
Pulmonary, Critical Care,
and Sleep Medicine, University of
Florida College of Medicine,
PO Box 100225, Gainesville,
FL 32610, USA
Fax +1 352-392-7088
Email brantml@medicine.ufl.edu

predicted (actual percentage varied according to the studies from 35% to 80%).⁵⁻¹⁴

Augmentation therapy with purified intravenous alpha-1 antitrypsin replaces the deficient protein and is the only currently approved treatment for AATD. Few observational studies have demonstrated a beneficial effect of augmentation therapy with alpha-1 antitrypsin, in reducing the rapid decline in lung function seen in patients with this condition.^{5,15,16} However, a randomized study in patients with moderate to severe emphysema demonstrated no changes in the annual FEV₁ decline in the placebo versus the treatment arm.¹⁷

We sought to examine the effect of alpha-1 antitrypsin augmentation therapy on FEV₁ decline, in AATD patients enrolled in the Alpha-1 Foundation DNA and Tissue Bank study.

Material and methods

The Alpha-1 Foundation DNA and Tissue Bank collected, from across the United States, medical information and human tissue of individuals with AATD, immediate relatives of individuals with AATD and subjects without the disease who were interested in the project.

The Alpha-1 Foundation DNA and Tissue Bank project is sponsored by the Alpha-1 Foundation and is physically located at the University of Florida College of Medicine, Gainesville, FL, USA. The Alpha-1 Foundation DNA and Tissue Bank protocol and analysis of the data presented in this article were approved by the University of Florida Institutional Review Board.

Upon enrollment, individuals signed an informed consent and completed a registration form as well as an extensive medical questionnaire. The answers written in the introductory questionnaire were reviewed in detail and corroborated during an initial phone interview with the study participant. If the individuals indicated that they agreed to be contacted, they were called annually to update their medical information.

FEV₁ measured in liters and percentage of predicted were recorded at the time of the initial medical questionnaire and during annual phone interviews. For the purpose of the current analysis, patients were included if they had a proven PI ZZ genotype (by Taqman allelic discrimination) and at least two recorded postbronchodilator FEV₁ measurements, 6 months apart or more. Patients not meeting the inclusion criteria or who underwent lung or liver transplant were excluded from the analysis. Great attention was put to assure high quality spirometric measurements following American Thoracic Society standards. Spirometry results that questioned the patient's effort during the test were not recorded.

All the recorded FEV₁ measurements were used to estimate the change in FEV₁ (Δ FEV₁). A change in FEV₁ (Δ FEV₁) is defined as the initial FEV₁ in L/m minus the FEV₁ obtained by random effects model. A positive Δ FEV₁ represents an increase in FEV₁ and a negative Δ FEV₁ corresponds to a decrease in FEV₁. We favored the use of Δ FEV₁ instead of decline in FEV₁ as we believe that a positive or negative Δ FEV₁ is easier to understand than a positive or negative rate of decline in FEV₁ or a positive or negative FEV₁ slope (5). The overall change in FEV₁ was defined as the difference in Δ FEV₁ between the augmented and the non-augmented group.

Patients were divided into 2 groups: 1) "augmented" (patients who were receiving augmentation therapy at time of the inclusion in the study), 2) "nonaugmented" (patients who were not receiving augmentation therapy at the time of the inclusion in the study).

The decision to treat or not treat AATD patients with augmentation therapy was made by the patients' physicians. The Alpha-1 Foundation DNA and Tissue Bank did not intervene in any way in the treatment plan of patients that participated in this study.

Patients were stratified in different groups according to the initial FEV₁ percentage of predicted. One stratification divided the patients in 3 groups (FEV₁ < 30%, 30% to 65% and >65% of predicted) using the most commonly described cut-off in the literature.^{15,16} In order to increase the numbers of patients in each group and provide more reliable conclusions, patients were also divided in 2 groups (FEV₁ < 50% or $\geq$ 50% of predicted).⁵ In addition we studied the group of patients with an initial FEV₁ of 35% to 49% of predicted, because this group was the one that benefit the most from augmentation therapy in the Alpha-1-Antitrypsin Deficiency Registry Study Group.⁵

Patients were also classified according to the smoking status. Current smoker was defined as the individual who was smoking at the time of the inclusion in the study. Ex-smoker was defined as a person who had not smoked for at least 3 months. Nonsmoker was defined as a subject who smoked less than 20 packs in his/her lifetime.

Statistical analysis

The decline in post-bronchodilator FEV₁ per year was estimated separately for each group by random effects models, which included FEV₁ as the outcome variable, FEV₁ (% of predicted value) and age at baseline, sex and smoking status as fixed parameters, and the individual patients and follow-up time as random effects parameters. The estimated Δ FEV₁ was

compared between the augmented and the non-augmented groups, and the *P*-value was calculated using Z-test. The analysis was repeated after including 26 patients in whom the smoking history was initially missing. This information was retrieved from an earlier version of the study database. T-test and Chi-square test or Fisher's exact test were used to compare continuous and categorical variables, respectively. The analysis of mortality at 5 years was performed with the use of logistic regression with age, gender, baseline FEV₁, presence of COPD and smoking status as covariates. Values are expressed as mean ($\pm$ standard error of the mean). A *P*-value < 0.05 was considered significant. All calculations were performed with the use of SAS software (version 6.10; SAS Institute Cary, NC, USA). Figures were created with Prism 5 for Windows version 5.00 (GraphPad Software, Inc., La Jolla, CA, USA).

Results

Baseline characteristics

Out of a total of 2,268 patients included in the Alpha-1 Foundation DNA and Tissue bank from January 2001 to April 2009, 777 patients had a Pi ZZ genotype. Of the patients with Pi ZZ genotype only 215 had 2 or more measurements of FEV₁ at least 6 months apart. We excluded 17 patients who had lung ($n = 15$) or liver transplantation ($n = 2$), and 8 patients who did not have the initial FEV₁ % of predicted, which was used as a baseline covariate in the model. Twenty-six patients had missing smoking history. For the purpose of our analysis we included 164 patients, in whom all the variables included in the random effects model were available (Figure 1).

The mean age at the time of inclusion in the study was 60 (± 0.73) years. The mean age at the time of diagnosis of AATD was 45.9 (± 0.72) years. The majority of patients (94%) were white (the rest did not report race) and 51.8% were females. The greater part of patients were ex-smokers ($n = 128$, 78%). Nonsmokers and current smokers constituted 20.8% ($n = 34$) and 1.2% ($n = 2$) of the individuals, respectively. Of the patients that smoked and in whom data was available ($n = 120$), the mean number of years exposed to smoke was 18.9 (± 0.74) years. The post-bronchodilator mean FEV₁ at baseline was 1.7 (± 0.07) liters and the mean initial FEV₁ percentage of predicted was 51.3 (± 2)%.

Follow-up

The mean (SEM; range) follow-up time was 41.7 (± 2.6 ; range: 6 to 268) months. The number of spirometries was 2, 3, and 4 in 67%, 18% and 15% of patients, respectively (median of 2). During the follow-up 5.5% ($n = 9$) patients died.

Augmented versus non-augmented patients

Of the patients included in the analysis, 124 (76%) stated that they were receiving augmentation therapy (augmented group) and 40 patients (24%) declared that they were not receiving augmentation therapy (non-augmented group) at the time of the introductory questionnaire. In the augmented group, this treatment was initiated a mean of 69.6 (± 6.7) months before the first FEV₁ measurement available in the database. 20 patients initiated this therapy after the first and before the second FEV₁ result. The augmentation therapy used was predominantly weekly intravenous Prolastin® (Talecris Biotherapeutics), in 88% of the patients. Less commonly the patients received Aralast® (Baxter) (10% of the patients) and Zemaira® (CSL-Behring) (2% of the patients). Data were available in only 48 patients (39%).

The group treated with augmentation therapy was older (61.3 versus 56.1 years, $P = 0.014$) and had higher percentage of ex-smokers individuals (84.7 versus 62.5%, $P < 0.001$). The presence of dyspnea, asthma and COPD (chronic obstructive pulmonary disease) was higher in the augmented group, leading to a higher use of inhaled bronchodilators and oxygen therapy (Table 1). The baseline post-bronchodilator FEV₁ either in liters (1.41 versus 2.44 L, $P < 0.001$) or percentage of predicted (43 versus 77%, $P < 0.001$) was lower in the augmented group (Table 1). No difference between the groups were noted in the age at the time of diagnosis, gender, race, number of years of smoking, exposure to fumes or dust at work, history of bronchiectasis, hepatitis and cirrhosis, use of inhaled or systemic corticosteroids and theophylline. In addition no difference between the groups were found in duration of follow-up, number of spirometries, family history of AATD or emphysema, year when the first spirometry was performed, as well as in the 5-year mortality rate.

Overall change in FEV₁ between the augmented versus the non-augmented group

When adjusted by age at baseline, sex, smoking status and baseline FEV₁ % of predicted the augmented group had a mean increase in Δ FEV₁ of 10.61 ± 21.4 mL/year. In comparison, the nonaugmented group had a mean decrease in Δ FEV₁ of -36.96 ± 12.1 mL/year ($P = 0.05$), constituting an overall change in FEV₁ (Δ FEV₁ in augmented minus Δ FEV₁ in the nonaugmented group) of 47.6 mL/year between the two groups (Table 2). When

Figure 1 Flow diagram of study population analysis.

adding the 26 patients in whom the smoking history was initially missing, the difference between the augmented and non-augmented groups remained significant (ΔFEV_1 in the augmented group: 8.92 ± 19.95 mL/year versus ΔFEV_1 in the non-augmented group: -34.96 ± 9.24 mL/year, overall FEV_1 change of 43.88 mL/year, $P = 0.046$).

Subgroup analysis

When patients were divided in 3 subgroups according to the initial FEV_1 % of predicted (<30%, 30% to 65% and >65%), a trend towards a beneficial effect of augmentation therapy was observed in the group with an initial FEV_1 between 30% to 65% (ΔFEV_1 augmented: 2.08 ± 24 mL/year

Table I Comparative table of the patients receiving versus not receiving augmentation therapy

	Augmented group	Non-augmented group	P
n (%)	124 (76%)	40 (24%)	
Age in years ^a	61.3 (0.7)	56.1 (1.9)	0.01
Age at diagnosis of AATD ^a	46.4 (0.8)	44.5 (1.8)	0.32
% Female gender	52.4%	50%	0.26
% White race	95.2	90%	0.58
% Ex-smokers	84.7%	62.5%	<0.001
% Current smokers	0%	5%	0.06
Number of years of smoking ^a	19.4 (0.9)	17.3 (1.4)	0.2
Exposure to dust or fumes at work	56.5%	45%	0.21
Dyspnea	91.9%	75%	0.004
Asthma	25%	10%	0.04
COPD (emphysema)	37.1%	15%	0.009
Bronchiectasis	12.1%	5%	0.25
Pneumonia	21%	12.5%	0.23
Pneumothorax	3.2%	2.5%	1
Hepatitis	2.4%	7.5%	0.16
Cirrhosis	0%	5%	0.06
FHx of AATD	63.7%	67.5%	0.66
FHx of emphysema	40.3%	47.5%	0.42
Inhaled bronchodilator	86.3%	55%	<0.001
Inhaled corticosteroid	59.7%	45%	0.1
Inhaled anticholinergics	6.5%	0%	0.2
Oral bronchodilators	11.3%	5%	0.24
Systemic corticosteroids	7.3%	2.5%	0.3
Theophylline	10.5%	5%	0.3
Oxygen therapy	50.8%	12.5%	<0.001
Baseline FEV ₁ (L/m) ^a	1.4 (0.1)	2.4 (0.2)	<0.001
Baseline FEV ₁ (% of predicted) ^a	43 (2)	77 (5)	<0.001
Duration of follow-up (months) ^a	43.6 (3.2)	35.7 (3.2)	0.19
Number of spirometries ^b	2	2	0.88
1st spirometry after 2004 ^c	50%	57.5%	0.41
Deceased patients	8 (6.4%)	1 (2.5%)	0.46

Abbreviation: AATD, alpha-1 antitrypsin deficiency; FHx, family history.

Notes: ^aContinuous values are provided as mean ($\pm$ SE); ^bMedian number of spirometries; ^cPercentage of patients in whom the first spirometry was performed after January 1, 2004.

versus Δ FEV₁ nonaugmented: -51.92 ± 18.1 mL/year; for an overall change in FEV₁ of 54 mL/year, $P = 0.07$) (Figure 2). Of note is that the patients with FEV₁ above 60% had higher rates of FEV₁ decline if they received augmentation therapy (Δ FEV₁ augmented: -108.7 ± 17.3 mL/year versus Δ FEV₁ non-augmented: -29.2 ± 15.29 mL/year; for an overall change in FEV₁ of 79.46 mL/year, $P < 0.001$) (Figure 2).

In the subset of patients with initial FEV₁ % of predicted between 30% and 65%, one influential subject in the augmented group was identified using diagnostic statistics

by PROC MIXED in SAS (SAS Institute). Omitting this subject the Δ FEV₁ was 11.88 ± 23.96 mL/year in the augmented group ($n = 78$) and -51.92 ± 18.14 mL/year in the non-augmented group, $P = 0.034$.

The analysis was repeated after adding 26 patients in whom the smoking history was initially missing. The inclusion of these patients did not modify the results for the <30% and >65% subgroups, however it made the difference, in the subgroup of patients with initial FEV₁% between 30% and 65%, statistically significant (Δ FEV₁ in the augmented group ($n = 89$): 6.82 ± 24.07 mL/year versus Δ FEV₁ in the

Table 2 Annual ΔFEV_1 for the augmented and the non-augmented groups

Stratification	Groups				P-value
	Augmented		Non-augmented		
	n	ΔFEV_1 (mL/year)	n	ΔFEV_1 (mL/year)	
Initial FEV ₁					
<30% pred	30	0.86 (17.63)	3	20.10 (31.06)	0.59
30%–65% pred	79	2.08 (24.03)	10	−51.92 (18.14)	0.07
>65% pred	15	−108.7 (17.29)	27	−29.24 (15.29)	0.0006
Initial FEV ₁					
<50% pred	88	38.30 (33.65)	8	−86.73 (45.37)	0.026
≥50% pred	36	−49.46 (15.88)	32	−32.78 (13.15)	0.42
Smoking					
Non-smokers	19	−25.06 (49.53)	15	−38.43 (12.12)	0.79
Ex-smokers	105	24.24 (25.72)	23	−41.19 (22.47)	0.05
Current smokers	0	–	2	–	–
Total	124	10.61 (21.37)	40	−36.96 (12.13)	0.05

Notes: Results shown in the parentheses are standard errors of the estimated change in FEV₁. A positive ΔFEV_1 represents an increase in FEV₁, and a negative ΔFEV_1 corresponds to a decrease in FEV₁.

non-augmented group: -49.44 ± 15.72 mL/year, for an overall change in FEV₁ of 56.3 mL/year, $P = 0.05$).

When patients were divided in 2 subgroups (<50% or ≥50%), only the subgroup with an initial FEV₁ <50% of predicted benefited from augmentation treatment (ΔFEV_1 augmented: 38.30 ± 33.7 mL/year versus ΔFEV_1 non-augmented: -86.73 ± 45.4 mL/year; for an overall change in FEV₁ overall change in FEV₁ of 125.03 mL/year, $P = 0.03$) (Figure 3). The inclusion of the patients with missing

smoking history did not alter the results of this particular analysis.

When patients were divided by the smoking status, the beneficial effects of augmentation therapy were noted only in the group of patients classified as ex-smokers (ΔFEV_1 augmented: 24.24 ± 25.7 mL/year versus ΔFEV_1 non-augmented: -41.19 ± 22.5 mL/year; for an overall change in FEV₁ of 65.4 mL/year, $P = 0.05$) (Figure 4). The patients that quit smoking did so $21.9 (\pm 1.02)$ years before

Figure 2 ΔFEV_1 (mL/year) in augmented and non-augmented patients by initial FEV₁ % of predicted (>65%, 30% to 65% and <30%). * $P = 0.0006$, ** $P = 0.07$.

Figure 3 Δ FEV₁ (mL/year) in augmented and non-augmented patients by initial FEV₁ % of predicted (<50% and $\geq$ 50%).* $P = 0.026$.

the inclusion in the study (range: 3.5 to 48.9 years). The inclusion of the patients with missing smoking history did not alter the results of this particular analysis.

Mortality

During the follow up, one patient died in the nonaugmented group and eight patients died in the augmented group. The 5-year mortality rate in this group of patients was 2.5% and 4% for the nonaugmented and the augmented group, respectively ($P = 0.581$, by logistic regression). Of note is that patients in the augmented group were older, and more commonly had COPD with lower FEV₁ and higher number of individuals required oxygen therapy.

Comparison with patients with 1 versus 2 or more spirometries

Patients that had one FEV₁ measurement ($n = 296$) had a higher mortality rate (9.8%) when compared to patients that had two or more FEV₁ recorded in the database (4.1%) ($P = 0.012$), despite the shorter follow-up time (one third less) in the former group of patients. This suggest a possible “survivor effect” on the rate of FEV₁ decline in patients who had 2 or more FEV₁ measurements.

Discussion

In the group of patients with AATD studied, augmentation therapy improved lung function, manifested as an increase

in the FEV₁, when results were adjusted by age, gender, smoking status and baseline FEV₁ percentage of predicted. The increase in FEV₁ was only observed in ex-smokers and patients with FEV₁ < 50% of predicted.

The FEV₁ rate of decline in the non-augmented group is consistent with the one observed in previous observational studies.^{8,10} It is unclear why we found an unusual increase in FEV₁ instead of a reduction in the FEV₁ decline as reported in previous studies.^{5,15,16} Possible explanations include anti-inflammatory effects of treatment with favorable effects over potential reversible processes such as bronchoconstriction and/or the use of different spirometry equipments. The first possible reason is supported by a higher incidence of asthma (25% versus 10%) and use of inhaled bronchodilators (86% versus 55%) in the group of patients receiving augmentation therapy. The use of different spirometry equipments, may have introduced variability in the results recorded. We cannot completely exclude the possibility of an increase in FEV₁ associated with a submaximal expiratory effort (unfortunately peak flow was not recorded). To the best of our knowledge the centers in which the spirometries were performed followed the American Thoracic Society standards and the best effort was made to insure the best quality and reliability of spirometry results. It is interesting to note that in the Alpha-1-Antitrypsin Deficiency Registry Study Group, some patients had a positive FEV₁ slope (in our case positive Δ FEV₁) when individual rates of FEV₁ were shown.⁵

Figure 4 ΔFEV_1 (mL/year) in augmented and non-augmented patients by smoking status * $P = 0.05$.

The increase in FEV_1 in augmented patients was observed only in ex-smokers and patients with an initial FEV_1 percentage of predicted $< 50\%$. Interestingly, augmented patients with an initial $FEV_1 > 65\%$ of predicted had a significant larger FEV_1 decline than nonaugmented patients, probably due to selection bias, as it is more likely to provide augmentation treatment to patients who have $FEV_1 > 65\%$ and an accelerated FEV_1 decline. Another possible explanation is based on the unusually low rate of FEV_1 decline in patients with $FEV_1 > 65\%$ who did not received augmentation therapy ($\Delta FEV_1 -29.24$ mL/year). This low value could have accentuated the differences in this subgroup of patients. A less likely possibility is a deleterious effect of augmentation therapy in AATD patients with $FEV_1 > 65\%$.

No difference in survival between the non-augmented and augmented group were observed when the 5-year mortality was adjusted for age, gender, smoking status, presence of COPD and baseline FEV_1 . As the overall sample is small and few patients died during the 3.5 year follow-up period, our study is underpowered to detect any difference in survival between the groups.

Few studies have compared the ΔFEV_1 in patients receiving versus not receiving alpha-1 antitrypsin augmentation therapy. Seersholm et al compared the ΔFEV_1 in AATD, among 97 Danish ex-smoker patients who did not received augmentation therapy, versus 198 German ex-smoker

patients who received this therapy. The authors showed a significant slower rate of decline in patients treated with augmentation therapy (mean ΔFEV_1 of 22 mL/year, $P = 0.02$). When stratified by the initial FEV_1 % of predicted, the authors showed a greater reduction in FEV_1 decline among patients with initial FEV_1 between 31% and 65% of predicted (mean overall change in FEV_1 of 22 mL/year, $P = 0.04$).¹⁵

The Alpha-1-Antitrypsin Deficiency Registry Study Group included 927 AATD patients and found no differences in ΔFEV_1 in patients receiving versus patients not receiving augmentation therapy (ΔFEV_1 4 mL/year, $P = 0.4$). However, a significant lower FEV_1 decline was observed in patients receiving augmentation therapy who had an initial FEV_1 value of 35% to 49% predicted (overall change in FEV_1 of 27 mL/year, $P = 0.03$) or of 30% to 64% predicted (overall change in FEV_1 of 18 mL/year, $P = 0.03$).⁵

Wencker et al analyzed the ΔFEV_1 in 96 patients with severe before and after the institution of augmentation therapy. Overall, there was a significant lower decline in ΔFEV_1 when patients received augmentation therapy in comparison with no treatment (ΔFEV_1 15 mL/year, $P = 0.019$). Patients with $FEV_1 < 30\%$ before initiation of therapy showed a significant reduction of the FEV_1 decline (overall change in FEV_1 of 31.3 mL/year $p < 0.0001$). No significant changes were noted in the group of patients with FEV_1 30% to 65% or $> 65\%$ of predicted.¹⁶

Dirksen et al randomized 26 Danish and 30 Dutch patients with AATD to receive albumin versus alpha-1 antitrypsin augmentation therapy. No significant difference in the annual FEV₁ change was noted between the groups (overall change in FEV₁ of -19.8 mL/year, $P=0.25$).¹⁷ The same authors recently reported the results of a randomized trial that included 77 patients with AATD that received alpha-1 antitrypsin augmentation therapy or placebo. They explored the effect of augmentation treatment on computed tomography lung density. A trend suggestive of treatment benefit in the group receiving augmentation therapy was noted when change in lung density by computed tomography was used as outcome. No differences were observed in the mean annual FEV₁ decrease between the treatment and placebo groups.¹⁸

Selection bias at the time of the inclusion and “survivor effect” may help explain some of the discrepancies among the subgroup of patients that benefited the most when treated with alpha-1 antitrypsin augmentation therapy. When stratified by the initial FEV₁ percentage of predicted the group of patients that benefited the most were the ones with FEV₁ 30% to 65%^{1,6} or FEV₁ < 30%.¹⁶ In our study, the subgroup of patients with an initial FEV₁ 35% to 65% of predicted showed a trend to benefit from augmentation therapy ($P=0.07$). This difference became statistically significant after adding 26 patients in whom the smoking history was initially missing ($P=0.05$) or when an influential subject in the augmented group was omitted from the analysis ($P=0.02$). The studies by Seersholm et al and Alpha-1-Antitrypsin Deficiency Registry Study Group observed a beneficial effect of augmentation therapy in the subgroup of patients with an initial FEV₁ 30% to 65% of predicted.^{5,15}

The majority of patients included in the previous studies were ex-smokers, especially in the group of patients that received augmentation therapy.⁵ Similarly in our study, 78% of the patients were ex-smokers and this percentage increase to 85% when only considering the augmented patients. Only two patients were current smokers at the time of inclusion. A significant overall change in FEV₁ was only noted in the group of patients that were ex-smokers. This difference is not attributable to a reduction in the rate of FEV₁ decline due to discontinuation of tobacco products as ex-smoker patients quit smoking an average of 21.9 years before the inclusion in the study (all ex-smoker patients quit smoking at least 3 years before their inclusion).

Non-smokers had a non significant difference in the rate of FEV₁ decline, probably due to a reduced effect of therapy, in patients with slower FEV₁ decline, or smaller sample size. Observational studies have shown no significant difference

in the rate of FEV₁ decline when ex-smokers were compared with non-smokers.⁸

The majority of patients included in our study received augmentation therapy (76%). Reasons for not receiving therapy included: 1) not recommended by physician ($n=10$), 2) recent diagnosis, 3) waiting to begin therapy, 4) financial reasons and 5) personal desire. The mean FEV₁ % of predicted for the patients who did not received therapy by physician recommendation was 95 (± 7)%, meanwhile for the rest of the patients in the nonaugmented group the mean (SE) FEV₁ % of predicted was 48 (± 2)%, ($P < 0.001$).

A similar percentage of AATD patients treated with augmentation therapy (70%) was reported by the Alpha-1-Antitrypsin Deficiency Registry. The main reasons for not receiving therapy in the registry were 1) not indicated or recommended by physician, 2) high cost, 3) receipt or anticipation of a lung transplant and 4) medical contraindication. Patients who did not receive augmentation therapy had higher FEV₁, less pulmonary symptoms, lower family income and were less likely to have insurance coverage (5).

Limitations of our study included 1) observational non-randomized study; 2) a possible selection bias, as only patients who had all the variables of interest recorded and who had two spirometries at least 6 months apart were included in the analysis (patients had a higher mortality rate if they only had one FEV₁ measurement in comparison with two or more, leading to an underestimation of the rate of FEV₁ decline, the so called “healthy survivor effect”); 3) spirometries were performed in different centers that used diverse equipments; 4) patients were divided in augmented and non-augmented group at the time of the inclusion in the study (some patients may have started or stopped therapy afterwards); 5) the criteria for starting treatment and compliance with therapy were not recorded, 6) the length of follow-up was relatively short (3.5 years), 7) other risk factors that may influence the rate of FEV₁ decline, such as bronchodilator response and respiratory exacerbation rates were not investigated.^{10,12,19–22}

In spite of the previous limitations, our study has a different research design, and the analysis of the data still supports the findings of previous studies, that showed an improvement in lung function in AATD patients receiving augmentation therapy. This study demonstrated that ex-smokers with FEV₁ < 50% benefited the most from alpha-1 antitrypsin augmentation therapy. In addition it provides “everyday practice” information about the characteristics of patients with AATD that received versus the ones that did not receive alpha-1 antitrypsin augmentation therapy.

Conclusion

Augmentation therapy improves lung function in patients with AATD when adjusted by age, gender, smoking status and baseline FEV₁ % of predicted. The beneficial effects were noted in ex-smoker patients with FEV₁ below 50% of predicted.

Acknowledgments

The authors acknowledge funding from the Alpha-1 Foundation.

Disclosures

The authors declare no conflicts of interest.

References

1. Brantly M, Nukiwa T, Crystal RG. Molecular basis of alpha-1-antitrypsin deficiency. *Am J Med*. 1988;84:13–31.
2. Gadek JE, Fells GA, Zimmerman RL, Rennard SI, Crystal RG. Antielastases of the human alveolar structures. Implications for the protease-antiprotease theory of emphysema. *J Clin Invest*. 1981;68:889–898.
3. Stockley RA. The pathogenesis of chronic obstructive lung diseases: implications for therapy. *QJM*. 1995;88:141–146.
4. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1-antitrypsin deficiency. *Am J Respir Crit Care Med*. 2003;168:818–900.
5. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Survival and FEV₁ decline in individuals with severe deficiency of alpha-1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. *Am J Respir Crit Care Med*. 1998;158:49–59.
6. Evald T, Dirksen A, Keittelmann S, Viskum K, Kok-Jensen A. Decline in pulmonary function in patients with alpha-1-antitrypsin deficiency. *Lung*. 1990;168:579–585.
7. Seersholm N, Kok-Jensen A, Dirksen A. Decline in FEV₁ among patients with severe hereditary alpha-1-antitrypsin deficiency type PiZ. *Am J Respir Crit Care Med*. 1995;152:1922–1925.
8. Piitulainen E, Eriksson S. Decline in FEV₁ related to smoking status in individuals with severe alpha-1-antitrypsin deficiency (PiZZ). *Eur Respir J*. 1999;13:247–251.
9. Janus ED, Phillips NT, Carrell RW. Smoking, lung function, and alpha-1-antitrypsin deficiency. *Lancet*. 1985;1:152–154.
10. Dawkins PA, Dawkins CL, Wood AM, Nightingale PG, Stockley JA, Stockley RA. Rate of progression of lung function impairment in alpha-1-antitrypsin deficiency. *Eur Respir J*. 2009;33:1338–1344.
11. Wu MC, Eriksson S. Lung function, smoking and survival in severe alpha-1-antitrypsin deficiency, PiZZ. *J Clin Epidemiol*. 1988;41:1157–1165.
12. Piitulainen E, Tornling G, Eriksson S. Effect of age and occupational exposure to airway irritants on lung function in non-smoking individuals with alpha-1-antitrypsin deficiency (PiZZ). *Thorax*. 1997;52:244–248.
13. Dowson LJ, Guest PJ, Stockley RA. Longitudinal changes in physiological, radiological, and health status measurements in alpha(1)-antitrypsin deficiency and factors associated with decline. *Am J Respir Crit Care Med*. 2001;164:1805–1809.
14. Eden E, Hammel J, Rouhani FN, et al. Asthma features in severe alpha-1-antitrypsin deficiency: experience of the National Heart, Lung, and Blood Institute Registry. *Chest*. 2003;123:765–771.
15. Seersholm N, Wencker M, Banik N, et al. Does alpha-1-antitrypsin augmentation therapy slow the annual decline in FEV₁ in patients with severe hereditary alpha-1-antitrypsin deficiency? *Eur Respir J*. 1997;10:2260–2263.
16. Wencker M, Fuhrmann B, Banik N, Konietzko N. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. *Chest*. 2001;119:737–744.
17. Dirksen A, Dijkman JH, Madsen F, et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. *Am J Respir Crit Care Med*. 1999;160:1468–1472.
18. Piitulainen E, Tornling G, Eriksson S. Environmental correlates of impaired lung function in non-smokers with severe alpha-1-antitrypsin deficiency (PiZZ). *Thorax*. 1998;53:939–943.
19. Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. *Chest*. 2000;118:1480–1485.
20. Silverman EK, Province MA, Rao DC, Pierce JA, Campbell EJ. A family study of the variability of pulmonary function in alpha-1-antitrypsin deficiency. Quantitative phenotypes. *Am Rev Respir Dis*. 1990;142:1015–1021.
21. Silverman EK, Province MA, Campbell EJ, Pierce JA, Rao DC. Variability of pulmonary function in alpha-1-antitrypsin deficiency: residual family resemblance beyond the effect of the Pi locus. *Hum Hered*. 1990;40:340–355.
22. Dirksen A, Piitulainen E, Parr DG, et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha-1-antitrypsin deficiency. *Eur Respir J*. 2009;33:1345–1353.

International Journal of COPD

Publish your work in this journal

The International Journal of COPD is an international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus is given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols.

Submit your manuscript here: <http://www.dovepress.com/international-journal-of-copd-journal>

Dovepress

This journal is indexed on PubMed Central, MedLine and CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.